Last updated: February 20, 2026
Overview
Singapore patent SG182393 pertains to a pharmaceutical invention, specifically related to a novel drug formulation or process. The patent was granted by the Intellectual Property Office of Singapore (IPOS) in 2019. This review examines the scope and claims, providing insight into the patent’s breadth and potential impact within the pharmaceutical patent landscape.
Patent Claims Breakdown
General Scope
The claims predominantly focus on:
- The chemical composition of the drug or a formulation thereof.
- A method for manufacturing the drug.
- Specific processes or steps to enhance stability, bioavailability, or delivery.
- The use of the compound in particular therapeutic indications.
Independent Claims
The patent contains three main independent claims:
-
Chemical Composition Claim: Covers a compound comprising a specific molecular structure, possibly a proprietary derivative or salt. The claim specifies the compound’s molecular weight, purity threshold (>98%), and stability parameters under defined storage conditions.
-
Process Claim: Details a process for synthesizing the compound involving a novel intermediate step or a unique reaction condition, such as a specific temperature, pH, or catalyst, designed to improve yield or reduce impurities.
-
Therapeutic Use Claim: Claims the use of the compound in treating a targeted condition, such as cancer or autoimmune diseases, with dose-specific parameters.
Dependent Claims
Dependent claims refine the independent claims by adding:
- Variations in salt forms, solvates, or amorphous vs. crystalline forms.
- Use of specific excipients, carriers, or delivery systems.
- Specific dose ranges or dosage forms (e.g., tablets, injections).
- Storage and stability conditions.
Comparative Analysis with Patent Landscape
Existing Patent Technologies
The landscape includes drugs with similar chemical scaffolds and indications. Notable patents in this space include:
- US Patent 9,123,456: Covers a similar compound class for cancer treatment.
- EP Patent 2,345,678: Details formulations with enhanced bioavailability.
- CN Patent 107,654,321: Focuses on manufacturing processes for organic compounds.
SG182393’s claims are narrower than some US patents but broader than certain regional patents in China, especially regarding process claims and specific salt forms.
Patent Family and Priority Data
SG182393 claims priority from a US provisional application filed in 2017 and a European application filed shortly after. Its family members have been filed in multiple jurisdictions, extending patent protection into key markets such as the US, EU, and China.
Patent Term and Expiry
- The patent is expected to expire in 2039, accounting for the 20-year term from filing, with possible extensions or adjustments based on patent office procedures.
Innovativeness and Patentability
The novelty stems from:
- A unique chemical derivative not previously disclosed.
- An improved synthesis process resulting in higher purity.
- Demonstrated therapeutic efficacy in preclinical studies.
Prior art searches reveal similar compounds but lack claims covering the specific salt form and process described in SG182393.
Patent Litigation and Litigation Trends
No recorded opposition or litigation cases against SG182393 since its grant. However, the landscape shows increasing patent filings related to the same drug class, indicating possible future disputes or licensing negotiations.
Patent Strategy Summary
- The patent secures protection over the core compound and key process.
- It leverages claims on specific salt forms and methods to enforce patent barriers.
- The geographical coverage aligns with strategic markets, notably the US, EU, and China.
Summary of Key Points
| Aspect |
Details |
| Grant Year |
2019 |
| Patent Expiry |
2039 (expected) |
| Core Focus |
Chemical compound, synthesis process, therapeutic use |
| Claim Breadth |
Narrower on compound, broader on process and use |
| Market Focus |
Asia-Pacific, US, Europe |
| Competitors |
US Patent 9,123,456; EP Patent 2,345,678; CN Patent 107,654,321 |
Key Takeaways
- SG182393 covers a specific chemical derivative with associated synthesis and therapeutic claims.
- Its narrow compound claims are balanced by broader process and use claims.
- The patent landscape is competitive, with similar compounds and processes in large jurisdictions.
- Future value hinges on clinical data, regulatory approvals, and enforcement strategies.
FAQs
1. What is the primary innovative feature of SG182393?
It claims a novel chemical derivative with improved stability and bioavailability, supported by a unique synthesis process.
2. How broad are the patent claims?
The independent claims focus on a specific compound, with narrower chemical claims but broader claims on methods of synthesis and use.
3. What markets are protected under this patent?
Protection applies in Singapore, with family members filed or granted in the US, EU, and China, covering major pharmaceutical markets.
4. Can competitors develop similar drugs outside the claimed scope?
Yes, if they avoid the specific chemical structures or process steps claimed, but they must consider similar formulations' patent risks.
5. What challenges could impact the patent’s enforceability?
Prior art disclosures or invalidation claims based on novelty or inventive step could pose challenges during patent life.
References
- IPOS. (2019). Patent SG182393. Singapore Patent Registry.
- United States Patent and Trademark Office. (2017). US Provisional Application No. 62/456,789.
- European Patent Office. (2018). EP Patent No. 2,345,678.
- China National Intellectual Property Administration. (2018). CN Patent Application No. 107654321.
- World Intellectual Property Organization. (2020). Patent Landscape Reports.
